Volume 84 Issue 34 | pp. 32-33
Issue Date: August 24, 2006

Life After Zocor

U.S. drug majors offered steady second-quarter results, despite shake-up in cholesterol market
Department: Business

Second-quarter financial results from U.S. pharmaceutical companies gave an early glimpse into life after Zocor, the blockbuster cholesterol drug from Merck that lost patent protection with just a week left in the quarter.

The news was bright for some—companies with newer drugs appear to be well—insulated from generic competition-and far from the dark scenario feared for Pfizer, whose cholesterol agent Lipitor was expected to be the most affected by patients switching to generic . . .

To view the rest of this content, please log in with your ACS ID.



Table: Drug Companies
Stronger earnings put U.S. company profit margins above European firms'.

Table is available as an image file.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society